Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd

₹ 122 -1.55%
20 May - close price
About

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Key Points

Product Portfolio:
The company manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic. It sells these formulations as suppositories, pessaries, capsules, tablets, and syrups. Its portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac. [1] [2]

  • Market Cap 1,283 Cr.
  • Current Price 122
  • High / Low 186 / 92.2
  • Stock P/E 15.2
  • Book Value 99.7
  • Dividend Yield 0.41 %
  • ROCE 11.7 %
  • ROE 8.36 %
  • Face Value 1.00

Pros

  • Company is almost debt free.

Cons

  • The company has delivered a poor sales growth of 3.27% over past five years.
  • Company has a low return on equity of 8.95% over last 3 years.
  • Company has high debtors of 198 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
167 189 172 206 185 160 212 201 198 184 218 210 198
147 150 148 158 179 135 158 157 170 149 176 181 177
Operating Profit 20 39 25 48 6 24 54 44 28 34 41 30 21
OPM % 12% 21% 14% 23% 3% 15% 26% 22% 14% 19% 19% 14% 11%
12 7 2 6 3 5 13 5 -24 4 5 15 12
Interest 2 2 2 1 5 1 1 2 2 2 4 1 2
Depreciation 4 5 5 5 5 6 6 7 7 7 7 8 8
Profit before tax 26 39 20 47 -1 22 59 40 -4 30 36 36 23
Tax % 11% 30% 21% 37% -561% 34% 27% 27% 24% 26% 28% 29% 29%
23 27 16 30 3 14 43 29 -5 22 26 26 17
EPS in Rs 1.89 2.48 1.33 2.68 0.32 1.41 4.05 2.64 -0.87 1.97 2.31 2.26 1.47
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
345 407 547 798 815 899 689 577 747 752 770 810
273 304 391 596 618 739 566 471 629 634 620 683
Operating Profit 71 103 156 203 197 160 123 107 118 117 151 127
OPM % 21% 25% 29% 25% 24% 18% 18% 18% 16% 16% 20% 16%
28 20 24 12 -8 35 26 20 -42 18 -0 36
Interest 18 16 19 20 23 4 8 6 5 10 7 8
Depreciation 11 11 13 20 21 9 13 17 17 19 26 29
Profit before tax 71 96 148 175 145 182 129 104 54 106 117 126
Tax % 42% 36% 32% 36% 39% 30% 26% 29% 57% 28% 30% 28%
41 61 100 113 89 127 95 74 23 77 82 90
EPS in Rs 3.97 5.81 8.00 7.95 5.70 11.99 9.43 6.64 1.45 6.80 7.21 8.00
Dividend Payout % 13% 12% 6% 8% 18% 8% 5% 8% 34% 7% 7% 6%
Compounded Sales Growth
10 Years: 7%
5 Years: 3%
3 Years: 3%
TTM: 5%
Compounded Profit Growth
10 Years: 3%
5 Years: -4%
3 Years: 44%
TTM: -11%
Stock Price CAGR
10 Years: 0%
5 Years: 6%
3 Years: 19%
1 Year: 12%
Return on Equity
10 Years: 12%
5 Years: 8%
3 Years: 9%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 10 10 10 10 10 10 10 10 10 10 10 11
Reserves 277 327 402 476 526 636 725 798 808 873 957 1,040
173 160 132 225 118 102 126 122 109 102 100 88
123 166 218 311 206 157 168 147 181 171 147 162
Total Liabilities 583 662 762 1,023 860 905 1,030 1,077 1,109 1,157 1,214 1,301
213 234 225 305 143 146 242 234 281 379 370 406
CWIP 4 0 9 4 0 47 0 2 22 3 8 21
Investments 0 0 0 0 0 0 0 0 2 8 4 4
365 428 527 714 717 712 788 840 803 768 832 870
Total Assets 583 662 762 1,023 860 905 1,030 1,077 1,109 1,157 1,214 1,301

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
41 38 113 289 18 40 47 64 135 34 152 106
-11 -29 -50 -249 48 -79 -40 -45 -103 -6 -133 -75
-8 -42 -40 -10 -76 17 -6 -21 -24 -25 -21 -30
Net Cash Flow 22 -34 23 30 -10 -22 0 -2 9 3 -1 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 228 222 201 116 134 187 290 293 192 187 192 198
Inventory Days 70 69 55 50 55 46 64 110 116 94 113 111
Days Payable 176 165 153 100 55 47 75 82 86 79 58 63
Cash Conversion Cycle 121 126 102 67 134 186 279 321 221 202 247 246
Working Capital Days 146 160 125 76 182 180 269 319 219 221 232 224
ROCE % 20% 23% 31% 29% 27% 26% 18% 12% 14% 12% 14% 12%

Shareholding Pattern

Numbers in percentages

7 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
34.51% 34.55% 34.46% 35.04% 35.12% 35.06% 34.97% 34.97% 34.90% 34.82% 35.10% 35.29%
17.17% 16.68% 16.53% 16.60% 16.50% 16.31% 15.35% 14.74% 13.24% 12.13% 13.51% 13.18%
6.65% 6.64% 6.63% 6.63% 6.62% 6.61% 6.60% 6.59% 6.58% 6.56% 6.55% 6.55%
41.67% 42.13% 42.35% 41.73% 41.73% 42.00% 43.08% 43.71% 45.27% 46.49% 44.84% 44.98%
No. of Shareholders 46,32745,75344,98343,04142,18243,23440,75845,15744,73752,93749,55849,517

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls